{"page":{"totalFilteredElements":33},"studies":[{"active":true,"description":"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL) IOM-100361","eudractNumber":null,"id":4638,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT03417115","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-05-03T12:36:45+02:00","shortTitle":"OPAL (IOM-100361)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Evaluation der DIGA consilium care bei Patientinnen mit Her 2 positiven Brustkrebs während einer Chemotherapie in Kombination mit einer Her 2 zielgerichteten Antikörper Therapie","eudractNumber":null,"id":8562,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05425550","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-06-01T09:40:37+02:00","shortTitle":"PRO2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positivem Mammakarzinom / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":7720,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-12T14:28:59+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positiven MammaCa / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":10616,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-13T08:39:41+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

Prospektive Beobachtungsstudie molekulares Tumorboard am CCC Mainfranken des Universitätsklinikums Würzburg

","eudractNumber":null,"id":7637,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"gio4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"giu4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"hau4","name":"Merkelzellkarzinom"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"Sequenzierungspanel","id":"mt_58"}],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-04-19T14:01:24+02:00","shortTitle":"Prospektive Beobachtungsstudie molekulares Tumorboard am CCC Mainfranken des Universitätsklinikums Würzburg","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Mammakarzinom des Mannes - Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit der GBG (German Breast Group) zur Diagnostik und Therapie des Mammakarzinoms des Mannes

DRKS00009536
","eudractNumber":null,"id":1491,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-04-01T14:01:18+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
Male breast cancer - A prospective registry study of the University Women's Hospital Magdeburg in cooperation with the GBG (German Breast Group) on the diagnosis and treatment of male breast cancer

DRKS00009536

","eudractNumber":null,"id":6191,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-09-08T13:56:24+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan (PROVIDENCE)","eudractNumber":null,"id":10995,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05573893","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-18T09:19:32+02:00","shortTitle":"Registerstudie PROVIDENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a partially double-blinded, multicenter, randomized, controlled superiority study

DRKS00030745
","eudractNumber":null,"id":9451,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05658172","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-25T08:46:57+01:00","shortTitle":"SURVIVE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospective, international, multicenter non-AMG/MPG study to detect possible markers for prediction of seroma development and risk assessment of a breast seroma after mastectomy with or without implant-based breast reconstruction","eudractNumber":null,"id":10643,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05899387","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-03-10T13:38:44+01:00","shortTitle":"SerMa","therapeutical":false,"therapyLines":[]}]}